Summary
Both peptides fall into a similar broad context as Metabolic peptides, although the details of how they are used and discussed still diverge. Both are often discussed in Metabolic and endocrine contexts, while Dulaglutide is more of a hormone peptide and MOTS-c is better described as a mitochondrial peptide. They also influence different molecular systems, with Dulaglutide tracking more closely to GLP-1 receptor while MOTS-c centers more on Mitochondrial membrane. Dulaglutide has a more engineered peptide origin, while MOTS-c is closer to mitochondrial-encoded background and their development context also differs, with Dulaglutide approved while MOTS-c is in Preclinical development. Dulaglutide takes the form of a peptide conjugate, whereas MOTS-c is closer to a linear peptide, while their sequence patterns also diverge, with Dulaglutide showing alpha-helical domain features and MOTS-c showing hydrophobic domain features.